G. Heller

G. Heller, S. Y. Yang, V. Prasad, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Organ-derived dendritic cells have differential effects on alloreactive T cells.

Christopher G. King, M. V. D. van den Brink, G. Heller, 2008, Blood.

The impact of gross total resection on local control and survival in high-risk neuroblastoma.

N. Cheung, G. Heller, S. Wolden, 2004, Journal of pediatric surgery.

Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.

G. Heller, N. Cheung, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience.

P. Maslak, R. Warrell, W. Miller, 1994, Leukemia.

Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.

W. Gerald, G. Heller, M. LaQuaglia, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recurrence and morbidity in differentiated thyroid carcinoma in children.

M. Brennan, G. Heller, P. Exelby, 1988, Surgery.

Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients

H. Scher, M. Fleisher, D. Danila, 2016, Cancer journal.

Factors associated with relapse and survival in Wilms tumor: a multivariate analysis.

N. Shukla, P. Steinherz, G. Heller, 2012, Journal of pediatric surgery.

Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.

R. Motzer, W. Fair, G. Bosl, 1992, The Journal of urology.

Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8

S. Larson, M. Rosenblum, G. Heller, 1993, Journal of Neuro-Oncology.

Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro.

G. Heller, B. Kushner, R. O'reilly, 1990, Medical and pediatric oncology.

All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study

E. Dmitrovsky, R. Warrell, W. Miller, 1994, Annals of Internal Medicine.

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

M. Harrison, M. Morris, H. Scher, 2021, European Urology Open Science.

Pediatric desmoid tumor: retrospective analysis of 63 cases.

G. Heller, S. Hajdu, L. Faulkner, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease

A. Greenberg, G. Heller, G. Murphy, 2004 .

Fludarabine‐based cytoreductive regimen and T‐cell‐depleted grafts from alternative donors for the treatment of high‐risk patients with Fanconi anaemia

G. Heller, A. Auerbach, S. Wolden, 2008, British journal of haematology.

Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.

H. Scher, G. Heller, J. Bono, 2017 .

DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1.

G. Heller, S. Y. Yang, V. Prasad, 1999, Blood.

Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions.

S. Mackinnon, G. Heller, B. Childs, 1999, Blood.

Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.

D. Scheinberg, E. Pamer, M. V. D. van den Brink, 2006, Blood.

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.

David S. K. Lu, H. Scher, M. Fleisher, 2017, European urology.

Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3.

B. Alter, G. Heller, J. Lipton, 1993, Blood.

Successful treatment of diamond‐blackfan anemia with interleukin 3

B. Alter, G. Heller, J. Lipton, 1993, Stem cells.

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Speci ﬁ c Antigen Across Five Randomized Phase III Clinical Trials

H. Scher, M. Fleisher, R. Dreicer, 2018 .

Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo

A. Houghton, P. Chapman, K. Panageas, 2011, Clinical Cancer Research.

LPAM ( (cid:1) 4 (cid:2) 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease

A. Greenberg, G. Heller, G. Murphy, 2004 .

An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment.

M. Arcila, G. Heller, M. Moore, 2010, Blood.

Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease.

G. Heller, James W. Young, A. Scaradavou, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high‐dose chemotherapy plus granulocyte‐macrophage colony‐stimulating factor a randomized trial

L. Norton, R. Motzer, J. Crown, 1993 .

A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children.

G. Heller, J. Groeger, M. Quaglia, 1994, Journal of pediatric surgery.

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.

M. Ladanyi, M. Berger, C. Rudin, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Seventh Edition of TNM Classification for Gastric Cancer

H. Scher, G. Heller, Kristofer L. Prepelica, 2011 .

Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.

R. Warrell, G. Heller, A. Eardley, 1994, Leukemia.

Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease

M. Perales, D. Weinstock, M. Chiu, 2007, Bone Marrow Transplantation.

Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts.

G. Heller, N. Flomenberg, T. Small, 1989, Blood.

Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer

M. Morris, H. Scher, O. Smaletz, 2006, Clinical Cancer Research.

The effect of age at diagnosis on outcome in rhabdomyosarcoma

E. Casper, M. Brennan, G. Heller, 1994, Cancer.

Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study.

L. Robison, A. Mertens, P. Mitby, 2004, The Journal of clinical endocrinology and metabolism.

Bone Mineral Density in Young Adult Survivors of Childhood Cancer

C. Sklar, G. Heller, J. Aisenberg, 1998, Journal of pediatric hematology/oncology.

Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts

G. Heller, N. Flomenberg, T. Small, 1989 .

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.

O. Abdel-Wahab, R. Levine, G. Heller, 2011, Blood.

Absence of the (cid:1) 7 Integrin Results in Less Graft-Versus-Host Disease Due to Decreased Homing of Alloreactive T Cells to Intestine

G. Heller, E. Waldman, Sydney X Lu, 2005 .

Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation.

C. Sklar, G. Heller, F. Boulad, 1995, Bone marrow transplantation.

Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?

N. Cheung, G. Heller, B. Kushner, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards

L. Schwartz, M. Morris, H. Scher, 2005, Clinical Cancer Research.

Outcomes with second-line chemotherapy in castrate metastatic prostate cancer

H. Scher, G. Heller, M. Fleming, 2005 .

Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate?

N. Cheung, G. Heller, B. Kushner, 1999, Medical and pediatric oncology.

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

M. Ladanyi, C. Rudin, M. Kris, 2021, Clinical Cancer Research.

Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities.

M. V. D. van den Brink, G. Heller, James W. Young, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants

J. Goldberg, M. Perales, G. Heller, 2013, Bone Marrow Transplantation.

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade

K. Hsu, G. Heller, James W. Young, 2016, Cancer Immunology Research.

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK 1 / 2 Blockade Running Title : DCs mitigate NK dysfunction from JAK 1 / 2 inhibition

K. Hsu, J. Chung, G. Heller, 2016 .

Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.

J. Gabrilove, M. Andreeff, J. Kolitz, 1989, Seminars in oncology.

Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.

P. Albers, H. Scher, G. Heller, 2010 .

Human Epidermal Growth Factor Receptor 2 as a Prognostic Indicator in Osteogenic Sarcoma

A. Huvos, J. Healey, G. Heller, 2001, Clinical orthopaedics and related research.

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Alexia Iasonos, Xiaoyu Jia, Deborah Schrag, 2009, Journal of the National Cancer Institute.

Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.

M. Perales, M. V. D. van den Brink, J. Chewning, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia.

E. Dmitrovsky, D. Scheinberg, R. Warrell, 1993, Blood.

Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.

L. Barnett, S. Mackinnon, G. Heller, 1996, Bone marrow transplantation.

Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation.

G. Papanicolaou, S. Seo, G. Heller, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis.

T. Polyak, G. Heller, B. Dupont, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma.

W. Gerald, G. Heller, M. LaQuaglia, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.

A. Huvos, J. Healey, E. Casper, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

C. Cordon-Cardo, H. Scher, N. Rosen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

G. Heller, James W. Young, C. Münz, 2004, The Journal of Immunology.

Osteogenic sarcoma with clinically detectable metastasis at initial presentation.

A. Huvos, J. Healey, G. Heller, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake

Danny F. Martinez, S. Larson, M. Morris, 2016, The Journal of Nuclear Medicine.

The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles.

G. Heller, S. Y. Yang, V. Prasad, 1999, Transplantation.

Comparison of Immune Reconstitution After Unrelated and Related T-Cell – Depleted Bone Marrow Transplantation : Effect of Patient Age and Donor Leukocyte Infusions

S. Mackinnon, G. Heller, B. Childs, 1998 .

T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.

J. Goldberg, M. Perales, R. Jenq, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.

G. Papanicolaou, M. Perales, M. V. D. van den Brink, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Genomic correlates of clinical outcome in advanced prostate cancer

Yi Mi Wu, M. Loda, P. Kantoff, 2019, Proceedings of the National Academy of Sciences.

LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease.

M. V. D. van den Brink, A. Greenberg, G. Heller, 2004, Blood.

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

M. Horowitz, K. Hsu, G. Heller, 2005, Blood.

T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

M. Sadelain, V. Ponomarev, G. Heller, 2007, Nature Medicine.

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

Janice Gabrilove, Glenn Heller, J. Gabrilove, 1991 .

Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin

Michel Sadelain, Lucio Luzzatto, Glenn Heller, 2000, Nature.

Growth in children after bone marrow transplantation for acute leukemia.

C. Sklar, G. Heller, F. Boulad, 1995, Blood.

Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8

G. Heller, N. Cheung, M. Barmada, 1999, International journal of cancer.

Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

S. Jhanwar, M. Perales, M. V. D. van den Brink, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pediatric rhabdomyosarcoma of the head and neck.

W. Gerald, D. Kraus, G. Heller, 1997, American journal of surgery.

Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.

B. Clarkson, G. Heller, E. Berman, 1990, Blood.

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.

H. Scher, G. Heller, M. Fazzari, 2000, Controlled clinical trials.

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

B. Taylor, M. Ladanyi, C. Rudin, 2020, Clinical Cancer Research.

Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.

M. Sadelain, G. Heller, Jinrong Qu, 2014, Blood.

Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics

C. Rudin, E. Stanchina, E. de Stanchina, 2019, Nature Cancer.

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.

H. Scher, M. Leversha, H. Lilja, 2011, European urology.

Interleukin-1 production following T-cell-depleted and unmodified marrow grafts.

G. Heller, P. Black, R. O'Reilly, 1996, Pediatric hematology and oncology.

Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL.

David A. Williams, L. Silverman, N. Shukla, 2019, Blood.

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

M. Ladanyi, C. Rudin, M. Kris, 2021, Clinical Cancer Research.

Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations.

D. Ho, S. Lewin, Linqi Zhang, 2002, Blood.

Allogeneic B one M arrow T ransplantation V ersus Chemotherapy f or t he T reatment o f C hildhood A cute Lymphoblastic L eukemia i n S econd R emission: A S ingle-Instituti on S tudy

P. Steinherz, G. Heller, T. Small, 1999 .

Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study.

P. Steinherz, G. Heller, T. Small, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer

Oscar Lin, Glenn Heller, Hans Lilja, 2009, Clinical Cancer Research.

Validation and clinical utility of prostate cancer biomarkers

S. Larson, M. Morris, H. Scher, 2013, Nature Reviews Clinical Oncology.

A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions.

G. Heller, A. Scaradavou, V. L. La Russa, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.

J. Eastham, M. Gleave, H. Beltran, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials

M. Morris, H. Scher, G. Heller, 2006, Nature Clinical Practice Oncology.

Clinical states in prostate cancer: toward a dynamic model of disease progression.

H. Scher, G. Heller, H I Scher, 2000, Urology.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2016, JAMA oncology.

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

David S. K. Lu, H. Scher, Yipeng Wang, 2018, JAMA oncology.

Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

P. Steinherz, G. Heller, M. Murphy, 1991, JAMA.

Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.

W. Leonard, M. V. D. van den Brink, G. Heller, 2010, Blood.

The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.

P. Marks, L. Butler, G. Heller, 2001, Cancer research.

Advances in Brief The Histone Deacetylase Inhibitor , CBHA , Inhibits Growth of Human Neuroblastoma Xenografts in Vivo , Alone and Synergistically with All-Trans Retinoic Acid 1

P. Marks, L. Butler, G. Heller, 2001 .

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

S. Larson, L. Schwartz, M. Morris, 2007, Clinical Cancer Research.

Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.

H. Scher, C. Higano, C. Sawyers, 2010 .

Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia.

L. Barnett, S. Mackinnon, G. Heller, 1994, Blood.

Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.

W. Gerald, J. Healey, E. Casper, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.

Amanda R. Kulick, C. Rudin, J. Wolchok, 2022, Immunity.

Leveraging CD39 To Identify Tumor-Reactive CD8 T cells In Human Lung Cancer

Maria R. Ward, Amanda R. Kulick, C. Rudin, 2022 .

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

H. Scher, M. Leversha, H. Lilja, 2007, Clinical Cancer Research.

CirculatingTumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

H. Scher, M. Leversha, H. Lilja, 2007 .

A competing‐risks nomogram for sarcoma‐specific death following local recurrence

M. Kattan, M. Brennan, G. Heller, 2003, Statistics in medicine.

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review.

S. Jhanwar, G. Heller, B. Kushner, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

J. Teruya-Feldstein, C. Hedvat, G. Heller, 2012, Blood.

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Xiaoyu Jia, Glenn Heller, Johann S de Bono, 2009, The Lancet. Oncology.

Concordance probability as a meaningful contrast across disparate survival times

S. Devlin, G. Heller, 2020, Statistical methods in medical research.

IFN-γ and Fas Ligand Are Required for Graft-versus-Tumor Activity against Renal Cell Carcinoma in the Absence of Lethal Graft-versus-Host Disease1

M. V. D. van den Brink, G. Heller, G. Murphy, 2007, The Journal of Immunology.

The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis

G. Heller, G. Heller, D. Armstrong, 1996, Cancer.

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

Glenn Heller, Lawrence Schwartz, Steven Larson, 2007, Clinical Cancer Research.

Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors.

W. Mason, M. Rosenblum, T. Merchant, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Danny F. Martinez, M. Loda, S. Larson, 2015, Clinical Cancer Research.

Zr-J 591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Danny F. Martinez, M. Loda, S. Larson, 2015 .

A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Danny F. Martinez, M. Loda, S. Larson, 2015 .

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.

J. Gabrilove, M. Andreeff, J. Kolitz, 1991, Blood.

graft-versus-host disease and induces Th2 deviation Absence of inducible costimulator on alloreactive T cells reduces

G. Heller, G. Murphy, V. Hubbard, 2013 .

Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.

M. V. D. van den Brink, G. Heller, G. Murphy, 2005, Blood.

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

H. Beltran, M. Morris, A. Armstrong, 2019, Journal of Clinical Oncology.

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

A. D'Amico, P. Kantoff, K. Pienta, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

E. Basch, M. Morris, H. Scher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.

P. Kantoff, N. Schultz, M. Morris, 2020, JCO precision oncology.

Reply to M. Fink

H. Scher, G. Heller, Kristofer L. Prepelica, 2011 .

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

P. Albers, H. Scher, G. Heller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Tomasz Burzykowski, Arturo Molina, Marc Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

P. Kantoff, S. Larson, H. Scher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.

P. Scardino, M. Morris, H. Scher, 2005, Urology.

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2017, Cancer research.

T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.

S. Mackinnon, G. Heller, B. Childs, 1998, Blood.

Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT

J. Goldberg, M. Perales, R. Jenq, 2010, Bone Marrow Transplantation.

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.

Julie L. Yang, M. Ladanyi, M. Berger, 2020, JAMA oncology.

Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants

B. Shank, G. Heller, C. Bordignon, 1989 .

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant

J. Teruya-Feldstein, M. Arcila, M. Perales, 2019 .

Lehmann Family of ROC Curves

Mithat Gönen, Glenn Heller, M. Gönen, 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.

Christopher G. King, D. Scheinberg, R. Jenq, 2010, Journal of the National Cancer Institute.

Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.

M. Perales, R. Jenq, M. V. D. van den Brink, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant

J. Goldberg, M. Perales, M. V. D. van den Brink, 2017, Leukemia & lymphoma.

T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission.

B. Shank, G. Heller, N. Flomenberg, 1992, Blood.

Direct evidence for new T-cell generation by patients after either T-cell–depleted or unmodified allogeneic hematopoietic stem cell transplantationsPresented in part in abstract form at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, December 2000.

D. Ho, S. Lewin, Linqi Zhang, 2002 .

The use of back-up units to enhance the safety of unrelated donor cord blood transplantation.

G. Heller, A. Scaradavou, S. Giralt, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

G. Heller, A. Scaradavou, T. Small, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.

M. Perales, M. Chiu, G. Heller, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis

G. Heller, B. Childs, T. Small, 1997, Bone Marrow Transplantation.

Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.

S. Larson, N. Cheung, G. Heller, 1994, Cancer research.

Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers

A. Drilon, C. Rudin, M. Kris, 2021, British Journal of Cancer.

Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.

S. Soignet, D. Scheinberg, R. Warrell, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid.

P. Maslak, D. Scheinberg, R. Warrell, 1994, Blood.

Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy

K. Hsu, G. Heller, R. O'reilly, 2022, Blood Advances.

A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.

M. Morris, H. Scher, G. Heller, 2007, The Journal of urology.

IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.

M. V. D. van den Brink, G. Heller, G. Murphy, 2007, Journal of immunology.

Leukocytosis a nd t he R etinoic A cid S yndrome i n P atients With A cute P romyelocytic L eukemia T reated W ith A rsenic Trioxide

S. Soignet, D. Scheinberg, R. Warrell, 2000 .

Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.

M. Ladanyi, M. Berger, C. Rudin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.

J. Ravetch, G. Heller, James W. Young, 2005, The Journal of clinical investigation.

Langerhans-Type Dendritic Cells Genetically Modified to Express Full-Length Antigen Optimally Stimulate CTLs in a CD4-Dependent Manner1

Michel Sadelain, James W. Young, N. Houghton, 2006, The Journal of Immunology.

Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib

L. Schwartz, E. Zabor, P. Chapman, 2015, Clinical Cancer Research.

Septicemia and Septic Shock in Pediatric Patients: 140 Consecutive Cases on a Pediatric Hematology‐Oncology Service

G. Heller, G. Heller, A. Brown, 1998, Journal of pediatric hematology/oncology.

Inference for the difference in the area under the ROC curve derived from nested binary regression models.

V. Seshan, M. Gönen, C. Moskowitz, 2016, Biostatistics.

Estimating the concordance probability in a survival analysis with a discrete number of risk groups

Q. Mo, G. Heller, Qianxing Mo, 2016, Lifetime data analysis.

Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome.

G. Heller, B. Kushner, M. Bonilla, 1994, Journal of pediatric surgery.

In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity

E. Pamer, G. Heller, M. Doubrovin, 2004, Clinical Cancer Research.

Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine.

J. Finlay, G. Heller, R. Jakacki, 1997, Medical and pediatric oncology.

High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery.

J. Finlay, G. Heller, P. Black, 1996, Bone marrow transplantation.

Second Malignant Neoplasms in Long‐Term Survivors of Childhood Rhabdomyosarcoma

C. Sklar, G. Heller, A. Scaradavou, 1995, Cancer.

Incorporating Follow-up Time in M-Estimation for Survival Data

G. Heller, 2004, Lifetime data analysis.

Analysis of Failure and Survival Data

G. Heller, 2003 .

Models Androgen-dependent and-independent Human Xenograft Response of Prostate Cancer to Anti-Her-2 / neu Antibody in Updated

C. Cordon-Cardo, H. Scher, D. Agus, 1999 .

Advances in Brief Response of Prostate Cancer to Anti-Her-2 / neu Antibody in Androgen-dependent and-independent Human Xenograft Models 1

C. Cordon-Cardo, H. Scher, D. Agus, 1999 .

A measure of explained risk in the proportional hazards model.

Glenn Heller, G. Heller, 2012, Biostatistics.

Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.

George Sgouros, Neal Rosen, Glenn Heller, 2003, Cancer research.

Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity.

N. Cheung, G. Heller, B. Kushner, 1991, Progress in clinical and biological research.

Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.

W. Gerald, J. Mora, N. Cheung, 2000, The Journal of molecular diagnostics : JMD.

Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile

A. Halpern, Xiwei Wu, S. Horwitz, 2018, Cancer Immunology Research.

Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications

S. Larson, M. Morris, H. Scher, 2015, Cancer.

Improving the Decision to Pursue a Phase 3 Clinical Trial by Adjusting for Patient-Specific Factors in Evaluating Phase 2 Treatment Efficacy Data

H. Scher, M. Kattan, G. Heller, 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

H. Beltran, M. Morris, E. Antonarakis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.

S. Larson, M. Morris, H. Scher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population

F. Saad, H. Scher, G. Heller, 2016, Clinical Cancer Research.

Expression of HER2/erbB-2 correlates with survival in osteosarcoma.

A. Huvos, J. Healey, G. Heller, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of NF-κB DNA binding suppresses myeloma growth via intracellular redox and tumor microenvironment modulation.

R. Feinman, G. Heller, Samedy Ouk, 2022, Molecular Cancer Therapeutics.

Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer

P. Kantoff, S. Larson, L. Schwartz, 2006 .

Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).

M. Gleave, F. Saad, M. Morris, 2021, European urology oncology.

Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy

H. Scher, G. Heller, S. Slovin, 2005, Clinical Cancer Research.

All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study

S. Soignet, T. Polyak, A. Fleischauer, 1997, Cancer Chemotherapy and Pharmacology.

Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.

R. Maki, M. Fleisher, G. Heller, 2013, Leukemia research.

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Nikolaus Schultz, Glenn Heller, Hans Lilja, 2014, European urology.

Quantifying the amount of variation in survival explained by prostate-specific antigen.

H. Scher, G. Heller, W. Kelly, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Proportional hazards regression with interval censored data using an inverse probability weight

Glenn Heller, G. Heller, 2011, Lifetime data analysis.

A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.

R. Warrell, P. O'dwyer, G. Heller, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER

J. Eastham, M. Gleave, H. Beltran, 2019, Journal of Urology.

Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.

M. Zelefsky, H. Scher, S. Leibel, 2004, Urology.

Primary peripheral nodal lymphoma in children

G. Heller, D. Filippa, N. Wollner, 1993, Cancer.

KIR and HLA genotypes have no identifiable role in single unit dominance following double unit umbilical cord blood transplantation

K. Hsu, G. Heller, J. Chou, 2014, Bone Marrow Transplantation.

Radiation Therapy Prostate-Specific Antigen Values following Surgery or Time to Detectable Metastatic Disease in Patients with Rising Updated

H. Scher, G. Heller, S. Slovin, 2005 .

Prevalence of vitamin D insufficiency in survivors of childhood cancer

C. Sklar, G. Heller, J. Chou, 2013, Pediatric blood & cancer.

A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer.

E. Basch, M. Morris, M. Milowsky, 2021, Clinical genitourinary cancer.

Response: Sample size and statistical comparisons of GVHD rates in pediatric Niemann-Pick disease patients.

M. V. D. van den Brink, R. Kolesnick, G. Heller, 2010, Blood.

Pairwise rank based likelihood for estimating the relationship between two homogeneous populations and their mixture proportion

J. Qin, G. Heller, 2005 .

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).

J. Eastham, M. Gleave, H. Beltran, 2019, Journal of Clinical Oncology.

Picking the winners in a sea of plenty.

H. Scher, G. Heller, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses.

Emily R. Levy, C. Ziegler, M. V. D. van den Brink, 2016, Cancer research.

Retrospective review of neoadjuvant chemotherapy for osteogenic sarcoma.

J. Healey, G. Heller, P. Meyers, 1992, Journal of the National Cancer Institute.

Evidence that appearance of thymulin in plasma follows lymphoid chimerism and precedes development of immunity in patients with lethal combined immunodeficiency transplanted with T cell-depleted haploidentical marrow.

S. Groshen, G. Heller, N. Flomenberg, 1990, Transplantation.

Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience.

P. Maslak, R. Warrell, W. Miller, 1994, Leukemia.

Risk assessment for severe hypocalcemia requiring hospitalization with denosumab.

M. Morris, H. Scher, G. Heller, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience.

P. Maslak, R. Warrell, W. Miller, 1994, Leukemia.

Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy.

M. Gleave, F. Saad, M. Morris, 2015 .

Age at onset of puberty following high-dose central nervous system radiation therapy.

A. Nirenberg, C. Sklar, G. Heller, 1996, Archives of pediatrics & adolescent medicine.

The Memorial Sloan-Kettering-New York-I1 Protocol

P. Steinherz, G. Heller, P. Meyers, 2006 .

Growth and Final Height After Treatment for Childhood Hodgkin Disease

C. Sklar, G. Heller, V. Papadakis, 1996, Journal of pediatric hematology/oncology.

Dose-intensity analysis and randomized trials.

G. Heller, N. Cheung, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment.

M. Arcila, G. Heller, M. Moore, 2010, Blood.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

J. Teruya-Feldstein, C. Hedvat, G. Heller, 2012, Blood.

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.

M. Sadelain, G. Heller, R. Brentjens, 2011, Cancer research.

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Ronald C. Chen, H. Beltran, M. Morris, 2021 .

Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering.

G. Heller, P. Meyers, V. Vlamis, 1993, Cancer treatment and research.

Inference on the Limiting False Discovery Rate and the P-value Threshold Parameter Assuming Weak Dependence between Gene Expression Levels within Subject

J. Qin, G. Heller, 2007, Statistical Applications in Genetics and Molecular Biology.

Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.

G. Altan-Bonnet, G. Heller, James W. Young, 2012, Blood.

Lehmann Family of ROC Curves

M. Gönen, G. Heller, 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

A comparison of estimators for regression with a censored response variable

Jeffrey S. Simonoff, Glenn Heller, J. Simonoff, 1990 .

Organ-derived dendritic cells have differential effects on alloreactive T cells.

Christopher G. King, M. V. D. van den Brink, G. Heller, 2008, Blood.

Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

M. Ladanyi, C. Rudin, M. Kris, 2020 .

Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.

Christopher G. King, D. Scheinberg, R. Jenq, 2010, Journal of the National Cancer Institute.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant.

J. Teruya-Feldstein, M. Arcila, M. Perales, 2020, The Journal of clinical investigation.

A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions.

G. Heller, A. Scaradavou, V. L. La Russa, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance)

J. Eastham, M. Morris, J. Mohler, 2021, The Journal of urology.